Latest news for Athenex Inc (OTC:ATNXQ) Stock

Athenex Inc

The Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) Coinbase Premium Index has turned negative, signaling a decrease in demand from U.S. investors.
What Happened: Crypto analytics firm CryptoQuant <a href="https://cryptoquant.com/insights/quicktake/66a22be57f92cc13ce598251-Bitcoin-Coinbase-Premium-Index-has-turned-negative?utm_source=telegram&amp;utm_medium=sns&amp;utm_campaign=quicktake&amp;utm_content=it-tech">reported</a> the negative turn in the Coinbase Premium Index.
This index measures the percentage difference between Bitcoin prices on Coinbase Pro (USD pair) and Binance (USDT pair). 
A positive premium typically indicates strong buying pressure from U.S. investors on Coinbase, while a negative value suggests waning interest.
The shift in U.S. investor sentiment coincides with a broader market downturn. Bitcoin, the world&#8217;s largest cryptocurrency by market capitalization, experienced a nearly 3.5% drop since midnight UTC, <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39955365/bitcoin-tumbles-3-ethereum-plunges-below-3-200-what-is-going-on-with-etfs">trading around $64,000</a>.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="930" height="458" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25103402/CQ.png" alt="" class="wp-image-457128" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25103402/CQ.png 930w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25103402/CQ-300x148.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25103402/CQ-768x378.png 768w" sizes="(max-width: 930px) 100vw, 930px" /></figure>
Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) saw an even steeper decline of over 8%, pulling the wider altcoin market down with it.
This cryptocurrency market downturn is occurring against a backdrop of global economic concerns. 
China&#8217;s second interest rate cut in a week has sparked worries about instability in the world&#8217;s second-largest economy. 
As a result, major European stock indices, including Germany&#8217;s DAX, France&#8217;s CAC and the eurozone&#8217;s Euro Stoxx 50, all fell by over 1.5%. In the U.S., futures tied to the tech-heavy Nasdaq 100 were slightly lower following the index&#8217;s 3% slide on Wednesday.
Also Read: <a href="https://www.benzinga.com/top-stories/24/07/39959562/tyler-winklevoss-kamala-harris-snubbing-bitcoin-conference-wont-be-forgotten-industry-will-show-no-m">Tyler Winklevoss: Kamala Harris Snubbing Bitcoin Conference Won&#8217;t Be Forgotten, Industry &#8216;Will Show No Mercy&#8217; In November</a>
Why It Matters: Despite the current market volatility, some analysts maintain a long-term bullish outlook on Bitcoin and the broader cryptocurrency market.
Jamie Coutts, Chief Crypto Analyst at Real Vision, drew <a href="https://x.com/Jamie1Coutts/status/1815337319911858357">parallels</a> between Bitcoin&#8217;s current trajectory and the early days of the NASDAQ:
&#8220;2009 is to Millennials what 1982 was to Boomers,&#8221; Coutts stated. &#8220;The NASDAQ launched in the 1970s but wasn&#8217;t considered a serious investment venue until the mid-1980s or early &#8217;90s. Since then, it has outperformed all other markets.&#8221;
Coutts argues that Bitcoin, launched in 2009, is entering its &#8220;mainstream moment&#8221; after a decade of skepticism. 
He views investing in Bitcoin as a &#8220;low-risk way to hedge against accelerating debasement,&#8221; while considering the broader blockchain asset class as &#8220;a bet on the secular trend of technological adoption.&#8221;
However, Coutts also emphasized the distinction between Bitcoin and other cryptocurrencies, noting they are &#8220;two very different assets with distinct risk profiles.&#8221; 
He advises investors to &#8220;size accordingly&#8221; but also to &#8220;zoom out,&#8221; suggesting that the current market conditions are part of a larger, ongoing secular bull market in the crypto space.
What&#8217;s Next: For those interested in further exploring the evolving landscape of digital assets and their integration into mainstream finance, Benzinga&#8217;s<a href="https://www.benzinga.com/events/digital-assets/agenda/"> Future of Digital Assets</a> event on Nov. 19 offers a timely platform for discussion and insight.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39938175/vice-president-harris-snubs-bitcoin-conference-would-have-been-a-disaster-for-her-shrugs-o">Vice President Harris Snubs Bitcoin Conference: &#8216;Would Have Been A Disaster For Her,&#8217; Shrugs Organizer</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

$BTC

$ETH

Bitcoin Demand From US Investors Wanes: 'Zoom Out And Size Accordingly,' Expert Tells Benzinga

Dover Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOV#NYSE">DOV</a>) reported&nbsp;second-quarter&nbsp;FY24 revenue of&nbsp;$2.178 billion, an increase of 4% Y/Y (+5% Y/Y organic), beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/n39952792/dover-reports-second-quarter-2024-results" rel="noreferrer noopener">consensus of&nbsp;$2.148 billion</a>.&nbsp;
Booking increased 15% Y/Y (+16% Y/Y organic) to $2.18 billion, book-to-bill ratio standing at <a target="_blank" href="https://investors.dovercorporation.com/static-files/34611d3c-d400-4692-adc2-c36be5ce5ffe" rel="noreferrer noopener">1.00x</a>.
Adjusted EPS was&nbsp;$2.36, up by&nbsp;15%&nbsp;Y/Y, beating <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">the consensus of&nbsp;$2.21</a>.
Segment earnings margin expanded 190 bps Y/Y to 22.1%. Total adjusted segment EBITDA margin expanded to&nbsp;23.8% from 21.9% a year ago.
Operating cash flow for the quarter totaled&nbsp;$203.7 million and free cash flow was&nbsp;$162.8 million.
Dover's President and Chief Executive Officer, Richard J. Tobin said, &#8220;Volume strength was broad-based across the portfolio, with four of our five operating segments posting top-line growth&#8230;Order trends continued their positive trajectory, bolstering our confidence in the second half&nbsp;outlook.&#8221;
2024 Outlook: Dover raised adjusted EPS from $9.00-$9.15 to $9.05-$9.20 (consensus of $9.10) and <a href="https://www.benzinga.com/calendars/guidance">revised revenue growth forecast from 2% &#8211; 4% to 3% &#8211; 4%.</a>
Price Action: DOV shares are up 5% at $185.19 at the last check Thursday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Earnings

Equities

Guidance

Movers

Dover's Earnings Boom: Q2 Results Shine, Lifts Full-Year Projections

Macro Economic Events

Global

Economics

U.S. Treasury's Yellen Says Believes We Have Constrained Russian Revenues With Sanctions, Oil Price Cap; U.S. Threat Of Sanctions On Financial Institutions Is Impairing Russia's Ability To Acquire Goods Needed For War Effort

RBC Capital analyst Drew McReynolds reiterates ROGERS COMMUNICATIONS INC (TSX:<a class="ticker" href="https://www.benzinga.com/stock/RCI#TSX">RCI</a>) with a Outperform and maintains C$65 price target.

Price Target

Reiteration

Analyst Ratings

TSX:RCI

TSX:RCI.B

RBC Capital Reiterates Outperform on ROGERS COMMUNICATIONS INC, Maintains C$65 Price Target

Macquarie analyst Chad Beynon maintains Monarch Casino &amp; Resort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRI#NASDAQ">MCRI</a>) with a Neutral and maintains $76 price target.

MCRI

Macquarie Maintains Neutral on Monarch Casino & Resort, Maintains $76 Price Target

To gain an edge, this is what you need to know today.
<img alt="" src="https://thearorareport.com/wp-content/uploads/2024/07/2024-07-25_08h55_20.png" style="height:394px; width:700px" />
<h3>GDP Brings Buying&nbsp;</h3>
Please <a href="https://thearorareport.com/chart-analysis-stock-market-ai-frenzy-cools-air-threat-yen-rises-qqq-mc-07252024">click here</a> for an enlarged&nbsp;chart of Invesco QQQ Trust Series 1 (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qqq#NASDAQ">QQQ</a>).
Note the following:
<ul>
<li>The chart shows a drop in QQQ.&nbsp; The drop in QQQ was triggered by speculative sentiment pulling back.&nbsp; As a reader&nbsp;of The Arora Report, you knew in advance that speculative sentiment could fall as a result of Tesla Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) earnings.</li>
<li>The chart shows that QQQ is approaching the support zone.</li>
<li>RSI on the chart shows that QQQ is now oversold.&nbsp; Oversold markets tend to bounce.</li>
<li>The chart shows that the volume was low on the selloff.&nbsp; This indicates a lack of conviction in selling.</li>
<li>Especially hard hit in yesterday&rsquo;s selloff were AI stocks as the AI frenzy cools.
<ul>
<li>AI stocks that are semiconductor stocks are partially hedged in The Arora Report&#39;s portfolio.&nbsp; The plan is to take profits on hedges if these stocks fall further.</li>
<li>As full disclosure, AI stocks in the portfolio include&nbsp;Apple Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aapl#NASDAQ">AAPL</a>), Analog Devices, Inc.&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adi#NASDAQ">ADI</a>), Applied Materials, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amat#NASDAQ">AMAT</a>), Amazon.com, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amzn#NASDAQ">AMZN</a>), Alphabet Inc Class C (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/goog#NASDAQ">GOOG</a>), Mongodb Inc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mdb#NASDAQ">MDB</a>), Meta Platforms Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meta#NASDAQ">META</a>), Microsoft Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/msft#NASDAQ">MSFT</a>), NVIDIA Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvda#NASDAQ">NVDA</a>), Micron Technology Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mu#NASDAQ">MU</a>), NXP Semiconductors NV (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxpi#NASDAQ">NXPI</a>), PG&amp;E Corp (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pcg#NYSE">PCG</a>), Quanta Services Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pwr#NYSE">PWR</a>), and Qualcomm Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qcom#NASDAQ">QCOM</a>).</li>
<li>At present, the AI stock with the best risk reward ratio is MSFT.</li>
<li>As full disclosure, AI and technology ETFs of interest in The Arora Report&#39;s ZYX Allocation Model Portfolio are Global X Artificial Intelligence &amp; Technology ETF (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aiq#NASDAQ">AIQ</a>), VanEck Semiconductor ETF (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smh#NASDAQ">SMH</a>), and iShares US Technology ETF (ARCA: IYW).</li>
<li>The AI ETF with the best risk reward ratio at present is AIQ.</li>
<li>Keep in mind, risk reward ratios are dynamic and change.</li>
</ul>
</li>
<li>Since AI stocks have run up so much in 2024, even with yesterday&rsquo;s selloff there is risk in buying AI stocks right here.</li>
<li>Q2 GDP-Adv came at 2.8% vs. 1.9% consensus.&nbsp; This stronger than expected data is bringing buying into the stock market.&nbsp; The reason is that a part of the drop in the stock market yesterday was on concerns that the economy was weakening too fast.</li>
<li>In The Arora Report analysis, investors should not be too enamored with buying on strong GDP data.&nbsp; The reason is that GDP is a lagging indicator.&nbsp; The Arora Report system that includes <a href="https://thearorareport.com/zyxmethod">ZYX Change Method</a> and <a href="https://thearorareport.com/ALLOCATION%2BMODELS.htm">ZYX Asset Allocation Model</a> is based on leading indicators. </li>
<li>Durable goods orders show weakness in transportation orders.&nbsp; Here are the details:
<ul>
<li>Headline durable orders came at -6.6% vs. 0.4% consensus.</li>
<li>Durable orders ex-transport came at 0.5% vs. 0.2% consensus.</li>
</ul>
</li>
<li>Initial jobless claims came at 235K vs. 240K consensus.&nbsp;&nbsp;Initial jobless claims is a leading indicator and carries heavy weight in our adaptive&nbsp;<a href="https://thearorareport.com/ALLOCATION%2BMODELS.htm" target="_blank">ZYX Asset Allocation Model</a>&nbsp;with inputs in&nbsp;<a href="https://thearorareport.com/unique-zyx-asset-allocation-4/" target="_blank">ten categories</a>.&nbsp; In plain English, adaptiveness means that the model changes itself with market conditions.&nbsp; Please&nbsp;<a href="https://thearorareport.com/unique-zyx-asset-allocation-3/" target="_blank">click here</a>&nbsp;to see how this is achieved.&nbsp; One of the reasons behind The Arora Report&rsquo;s unrivaled performance in both bull and bear markets is the adaptiveness of the model.&nbsp; Most models on Wall Street are static.&nbsp; They work for a while and then stop working when market conditions change.</li>
<li>The yen is rising on expectations that the Bank of Japan will raise rates.&nbsp; The rising yen is hammering gold, bitcoin, and oil.&nbsp; This is also bringing selling into the U.S. stock market as many funds borrow in yen and buy U.S. stocks.&nbsp; As full disclosure, there is a position in yen ETF&nbsp;Invesco CurrencyShares Japanese Yen Trust&nbsp;(ARCA:&nbsp;FXY) in The Arora Report&#39;s ZYX Allocation Model Portfolio.&nbsp;&nbsp;</li>
</ul>
<h3>Stunning Yen Rise</h3>
The Japanese currency yen is experiencing a stunning rise, reaching its highest level in two months against the dollar.&nbsp; The reason is an expectation that the interest rate gap between the U.S. and Japan will narrow.
<h3>First Ever Joint Air Threat</h3>
For the first time ever, two Chinese and two Russian aircraft operating together challenged U.S. aircraft in Alaska.&nbsp; This indicates that China and Russia sense weakness in the U.S. and are getting bolder.&nbsp; 
The momo crowd is oblivious, but prudent investors should pay attention to the protection band &ndash; this is one of the many geopolitical situations that is taken into account when determining the protection band.
<h3>Surprise China Rate Cut</h3>
The People&rsquo;s Bank of China (PBOC), in a surprise, cut the interest rate on one year loans by 20 basis points to 2.3%.&nbsp; This indicates that PBOC is stepping up to support China&rsquo;s economy in the wake of slowing Chinese consumers.
<h3>Magnificent Seven Money Flows</h3>
In the early trade, money flows are positive in AMZN, META, and TSLA.
In the early trade, money flows are neutral in AAPL and MSFT.
In the early trade, money flows are negative in GOOG and NVDA.
In the early trade, money flows are negative in SPDR S&amp;P 500 ETF Trust (ARCA:SPY) and Invesco QQQ Trust Series 1 (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qqq#NASDAQ">QQQ</a>).
<h3>Momo Crowd And Smart Money In Stocks</h3>
Investors can gain an edge by knowing money flows in SPY and QQQ. &nbsp;Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil. &nbsp;The most popular ETF for gold is SPDR Gold Trust (ARCA:GLD). &nbsp;The most popular ETF for silver is iShares Silver Trust (ARCA:SLV). &nbsp;The most popular ETF for oil is United States Oil ETF (ARCA:USO).
<h3>Bitcoin</h3>
Buying in Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) on the Trump strategic reserve rumor is being countered by rising yen bringing selling into bitcoin.&nbsp;&nbsp;
<h3>Protection Band And What To Do Now</h3>
It is important for investors to look ahead and not in the rearview mirror.
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.&nbsp; The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp; If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp; When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.
<h3>Traditional 60/40 Portfolio</h3>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.
This article is from an unpaid external contributor. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.

Forex

Markets

Trading Ideas

General

AAPL

AMAT

AMZN

GOOG

MSFT

NVDA

NXPI

QCOM

TSLA

AI Frenzy Cools, Yen Hammers Gold And Bitcoin, First Ever Joint Air Threat From Russia And China

Macquarie analyst Chad Beynon maintains Las Vegas Sands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>) with a Outperform and lowers the price target from $58 to $56.

Macquarie Maintains Outperform on Las Vegas Sands, Lowers Price Target to $56

RBC Capital analyst Sam Crittenden maintains TECK RESOURCES LIMITED (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TECK#TSX">TECK</a>) with a Outperform and lowers the price target from C$91 to C$88.

TECK

TSX:TECK

TSX:TECK.B

RBC Capital Maintains Outperform on TECK RESOURCES LIMITED, Lowers Price Target to C$88

WIIM

Tyler Technologies shares are trading higher after the company reported better-than-expected Q2 adjusted EPS and sales.

Deep-pocketed investors have adopted a bullish approach towards Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AMGN usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 12 extraordinary options activities for Amgen. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 58% leaning bullish and 33% bearish. Among these notable options, 3 are puts, totaling $131,892, and 9 are calls, amounting to $509,076.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $270.0 and $400.0 for Amgen, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Amgen options trades today is 710.62 with a total volume of 2,420.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Amgen's big money trades within a strike price range of $270.0 to $400.0 over the last 30 days.
<h3>Amgen 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721919988_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$37.0</td>
<td>$35.35</td>
<td>$37.0</td>
<td>$370.00</td>
<td>$136.9K</td>
<td style="text-align: right;">63</td>
<td style="text-align: right;">37</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$85.0</td>
<td>$81.5</td>
<td>$83.81</td>
<td>$270.00</td>
<td>$83.8K</td>
<td style="text-align: right;">706</td>
<td style="text-align: right;">10</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$9.1</td>
<td>$7.9</td>
<td>$9.15</td>
<td>$325.00</td>
<td>$64.7K</td>
<td style="text-align: right;">556</td>
<td style="text-align: right;">71</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/02/24</td>
<td>$6.25</td>
<td>$6.0</td>
<td>$6.0</td>
<td>$345.00</td>
<td>$63.6K</td>
<td style="text-align: right;">556</td>
<td style="text-align: right;">338</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$11.9</td>
<td>$9.85</td>
<td>$10.0</td>
<td>$400.00</td>
<td>$50.0K</td>
<td style="text-align: right;">66</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>

<h3>About Amgen</h3>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
After a thorough review of the options trading surrounding Amgen, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Amgen's Current Market Status</h3>
<ul>
<li>With a volume of 618,337, the price of AMGN is up 0.12% at $336.0. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 12 days.</li>
</ul>
<h3>Expert Opinions on Amgen</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $321.5.
<ul>
<li>Consistent in their evaluation, an analyst from Argus Research keeps a Buy rating on Amgen with a target price of $340. </li>
<li>Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Amgen with a target price of $303. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Amgen options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

AMGN

Market Whales and Their Recent Bets on AMGN Options

High-rolling investors have positioned themselves bullish on Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in GILD often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern.
The sentiment among these major traders is split, with 55% bullish and 33% bearish. Among all the options we identified, there was one put, amounting to $27,798, and 8 calls, totaling $322,062.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $55.0 to $78.0 for Gilead Sciences during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Gilead Sciences stands at 1447.83, with a total volume reaching 4,990.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Gilead Sciences, situated within the strike price corridor from $55.0 to $78.0, throughout the last 30 days.
<h3>Gilead Sciences 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721919980_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$1.66</td>
<td>$1.65</td>
<td>$1.65</td>
<td>$77.50</td>
<td>$62.7K</td>
<td>2.5K</td>
<td>149</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/02/24</td>
<td>$1.05</td>
<td>$1.0</td>
<td>$1.05</td>
<td>$78.00</td>
<td>$52.5K</td>
<td>18</td>
<td>761</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$15.8</td>
<td>$14.9</td>
<td>$15.8</td>
<td>$60.00</td>
<td>$47.4K</td>
<td>925</td>
<td>30</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/02/24</td>
<td>$0.77</td>
<td>$0.75</td>
<td>$0.77</td>
<td>$78.00</td>
<td>$34.8K</td>
<td>18</td>
<td>2.6K</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$9.7</td>
<td>$9.3</td>
<td>$9.51</td>
<td>$70.00</td>
<td>$33.2K</td>
<td>3.0K</td>
<td>41</td>
</tr>
</tbody>
</table>

<h3>About Gilead Sciences</h3>
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
After a thorough review of the options trading surrounding Gilead Sciences, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Gilead Sciences's Current Market Status</h3>
<ul>
<li>With a volume of 3,365,071, the price of GILD is up 2.73% at $75.51. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 14 days.</li>
</ul>
<h3>What Analysts Are Saying About Gilead Sciences</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $79.0.
<ul>
<li>An analyst from Raymond James upgraded its action to Outperform with a price target of $93. </li>
<li>An analyst from Cantor Fitzgerald has decided to maintain their Neutral rating on Gilead Sciences, which currently sits at a price target of $70. </li>
<li>Reflecting concerns, an analyst from RBC Capital lowers its rating to Sector Perform with a new price target of $74.</li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Gilead Sciences with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

GILD

This Is What Whales Are Betting On Gilead Sciences

Investors with a lot of money to spend have taken a bearish stance on Constellation Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CEG, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 10 options trades for Constellation Energy.
This isn't normal.
The overall sentiment of these big-money traders is split between 20% bullish and 70%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $36,000, and 9, calls, for a total amount of $591,163.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $140.0 to $240.0 for Constellation Energy over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Constellation Energy's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Constellation Energy's whale trades within a strike price range from $140.0 to $240.0 in the last 30 days. 
<h3>Constellation Energy Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721919975_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CEG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$3.9</td>
<td>$3.7</td>
<td>$3.7</td>
<td>$185.00</td>
<td>$281.7K</td>
<td>1.8K</td>
<td style="text-align: right;">519</td>
</tr>
<tr>
<td>CEG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$5.2</td>
<td>$4.9</td>
<td>$5.2</td>
<td>$240.00</td>
<td>$52.6K</td>
<td>1.1K</td>
<td style="text-align: right;">105</td>
</tr>
<tr>
<td>CEG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$4.2</td>
<td>$4.0</td>
<td>$4.01</td>
<td>$185.00</td>
<td>$52.5K</td>
<td>1.8K</td>
<td style="text-align: right;">317</td>
</tr>
<tr>
<td>CEG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$4.7</td>
<td>$4.4</td>
<td>$4.4</td>
<td>$185.00</td>
<td>$50.1K</td>
<td>1.8K</td>
<td style="text-align: right;">38</td>
</tr>
<tr>
<td>CEG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$3.9</td>
<td>$3.7</td>
<td>$3.7</td>
<td>$185.00</td>
<td>$43.1K</td>
<td>1.8K</td>
<td style="text-align: right;">446</td>
</tr>
</tbody>
</table>

<h3>About Constellation Energy</h3>
Constellation Energy Corp offers energy solutions. It provides clean energy and sustainable solutions to homes, businesses, the public sector, community aggregations, and a range of wholesale customers (such as municipalities, cooperatives, and other strategics). The company offers comprehensive energy solutions and a variety of pricing options for electric, natural gas, and renewable energy products for companies of any size.
After a thorough review of the options trading surrounding Constellation Energy, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Constellation Energy</h3>
<ul>
<li>Trading volume stands at 1,984,105, with CEG's price down by -1.96%, positioned at $171.65.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 12 days.</li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Constellation Energy options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Spotlight on Constellation Energy: Analyzing the Surge in Options Activity

JP Morgan analyst Bill Peterson maintains TECK RESOURCES LIMITED (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TECK#TSX">TECK</a>) with a Overweight and lowers the price target from C$76 to C$74.

JP Morgan Maintains Overweight on TECK RESOURCES LIMITED, Lowers Price Target to C$74

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Baird increased Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) price target from $200 to $240. Baird analyst William Power maintained an Outperform rating. Apple shares fell 0.1% to trade at $218.51 on Thursday. <a href="https://www.benzinga.com/quote/AAPL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities raised the price target for ServiceNow, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) from $750 to $780. Truist Securities analyst Joel Fishbein maintained a Hold rating. ServiceNow shares gained 11.9% to trade at $817.75 on Thursday. <a href="https://www.benzinga.com/quote/NOW/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan cut the price target for Illinois Tool Works Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITW#NYSE">ITW</a>) from $275 to $267. JP Morgan analyst Tami Zakaria maintained an Overweight rating. Illinois Tool Works shares gained 1.4% to trade at $242.61 on Thursday. <a href="https://www.benzinga.com/quote/ITW/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Cantor Fitzgerald raised the price target for HCA Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) from $335 to $392. Cantor Fitzgerald analyst Sarah James maintained an Overweight rating. HCA Healthcare shares rose 2.6% to trade at $352.73 on Thursday. <a href="https://www.benzinga.com/quote/HCA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel boosted Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) price target from $600 to $615. Stifel analyst Daniel Arias maintained a Buy rating. Thermo Fisher Scientific shares rose 3.3% to trade at $593.57 on Thursday. <a href="https://www.benzinga.com/quote/TMO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Oppenheimer raised the price target for AT&amp;T Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>) from $21 to $23. Oppenheimer analyst Timothy Horan maintained an Outperform rating. AT&amp;T shares rose 2.1% to trade at $19.56 on Thursday. <a href="https://www.benzinga.com/quote/T/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keefe, Bruyette &amp; Woods raised Renasant Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNST#NYSE">RNST</a>) price target from $34 to $36. Keefe, Bruyette &amp; Woods analyst Catherine Mealor maintained a Market Perform rating. Renasant shares fell 1% to trade at $35.55 on Thursday. <a href="https://www.benzinga.com/quote/RNST/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity boosted Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) price target from $83 to $88. Canaccord Genuity analyst William Plovanic maintained a Buy rating. Boston Scientific shares fell 1.6% to trade at $76.53 on Thursday. <a href="https://www.benzinga.com/quote/BSX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barclays cut NICE Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NICE#NASDAQ">NICE</a>) price target from $320 to $286. Barclays analyst Tavy Rosner maintained an Overweight rating. NICE shares gained 0.6% to trade at $181.99 on Thursday. <a href="https://www.benzinga.com/quote/NICE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird cut Amphenol Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>) price target from $72 to $70. Baird analyst Luke Junk maintained an Outperform rating. Amphenol shares rose 0.2% to trade at $62.12 on Thursday. <a href="https://www.benzinga.com/quote/APH/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39954998/over-1m-bet-on-united-security-bancshares-check-out-these-3-stocks-insiders-are-buying">Over $1M Bet On United Security Bancshares? Check Out These 3 Stocks Insiders Are Buying</a></li>
</ul>

NICE

RNST

Apple To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Thursday

Over the past 24 hours, Wrapped Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WBTC</a>) price has fallen 3.3% to $64,582.00. This is opposite to its positive trend over the past week where it has experienced a 1.0% gain, moving from $63,972.23 to its current price. 
The chart below compares the price movement and volatility for Wrapped Bitcoin over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1721919825_0.png" alt="price_chart" />
The trading volume for the coin has climbed 64.0% over the past week, moving opposite, directionally, with the overall circulating supply of the coin, which has decreased 0.48%. This brings the circulating supply to 154 thousand, which makes up an estimated 100.0% of its max supply of 154 thousand. According to our data, the current market cap ranking for WBTC is #14 at $9.98 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1721919825_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$WBTC

Wrapped Bitcoin Down More Than 3% Within 24 hours

LKQ Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LKQ#NASDAQ">LKQ</a>) shares are trading lower on Thursday after the company <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">reported second-quarter results.</a>
The company reported adjusted earnings per share of 98 cents, missing <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g39952075/lkq-corporation-announces-results-for-second-quarter-2024" rel="noreferrer noopener">the analyst consensus of $1.03</a>. Quarterly revenues of $3.71 billion (+7.6%), missed the street view of $3.87 billion.
Net income&nbsp;for the second quarter of 2024 was $185&nbsp;million compared to $281&nbsp;million <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">for the same period of 2023.</a>
Cash flow from operations and free cash flow&nbsp;were $213 million and $133 million, respectively, for the second quarter of 2024.&nbsp;
As of June-end, the balance sheet reflected total debt of $4.3&nbsp;billion and total leverage was 2.3x EBITDA.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/cryptocurrency/24/07/39958813/surprise-q2-gdp-growth-inflation-eases-economy-is-much-stronger-than-people-realize-7-etfs" rel="noreferrer noopener">Surprise Q2 GDP Growth, Inflation Eases — &#8216;Economy Is Much Stronger Than People Realize&#8217;: 7 ETFs On The Move</a>
During the second quarter, the company returned over $200&nbsp;million to its shareholders by investing $125&nbsp;million to repurchase 2.9&nbsp;million shares of its common stock and distributing approximately $80&nbsp;million in cash dividends.&nbsp;
On July 23, the company declared a quarterly cash dividend of $0.30 per share of common stock, payable on August 29, 2024.
&#8220;Based on a projected continuation of the revenue headwinds we experienced in the first half of 2024, we are lowering our full year&nbsp;guidance. While we have taken actions to reduce costs and protect our margins and cash flows, the benefits are not expected to offset the full impact of the lower revenue expectation,&#8221; stated CFO Rick Galloway.&nbsp;
Outlook: LKQ lowered its FY24 organic revenue growth outlook for parts and services from<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener"> 2.5%- 4.5% to (1.25%) &#8211; 0.25%.</a>
LKQ lowered its FY24 adjusted EPS outlook from $3.90 &#8211; $4.20 to $3.50 &#8211; $3.70 versus the $3.92 estimate.
Price Action: LKQ shares are trading lower by 12.5% to $38.91 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/39956426/tractor-supplys-q2-sales-miss-tightens-outlook-ceo-lawton-highlights-creating-more-separation-betwe" target="_blank" rel="noreferrer noopener">Tractor Supply&#8217;s Q2 Sales Miss, Tightens Outlook; CEO Lawton Highlights &#8216;Creating More Separation Between Us And Our Competition&#8217;</a></li>
</ul>

LKQ Slumps After Disappointing Q2 Results, Full-Year Outlook Cut: Details

BNB's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/bnb/usd">BNB</a>) price has decreased 3.73% over the past 24 hours to $565.61, continuing its downward trend over the past week of -1.0%, moving from $565.54 to its current price. 
The chart below compares the price movement and volatility for BNB over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1721919756_0.png" alt="price_chart" />
The trading volume for the coin has risen 41.0% over the past week diverging from the circulating supply of the coin, which has decreased 0.21%. This brings the circulating supply to 153.86 million, which makes up an estimated 76.93% of its max supply of 200.00 million. According to our data, the current market cap ranking for BNB is #4 at $87.02 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1721919756_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$BNB

BNB Falls More Than 3% In 24 hours

Over the past 24 hours, Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) price has fallen 3.01% to $64,731.00. This is opposite to its positive trend over the past week where it has experienced a 1.0% gain, moving from $63,771.94 to its current price. 
The chart below compares the price movement and volatility for Bitcoin over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1721919746_0.png" alt="price_chart" />
The trading volume for the coin has increased 42.0% over the past week. while the overall circulating supply of the coin has decreased 0.25% This puts its current circulating supply at an estimated 93.96% of its max supply, which is 21.00 million. The current market cap ranking for BTC is #1 at $1.28 trillion.
<img src="https://www.benzinga.com/files/images/story/2024/1721919746_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Bitcoin Falls More Than 3% In 24 hours

Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $41.88, with a high estimate of $57.00 and a low estimate of $25.00. Highlighting a 8.72% decrease, the current average has fallen from the previous average price target of $45.88. 
<img src="https://www.benzinga.com/files/images/story/2024/1721919719_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Pacira BioSciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Les Sulewski</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$30.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$25.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$43.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$57.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$57.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$38.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$43.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Pacira BioSciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Pacira BioSciences compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Pacira BioSciences's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Pacira BioSciences's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PCRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Pacira BioSciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Pacira BioSciences's Background</h2>
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
<h3>A Deep Dive into Pacira BioSciences's Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Pacira BioSciences displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 4.23%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Pacira BioSciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 5.37%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Pacira BioSciences's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.02%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Pacira BioSciences's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.57%, the company showcases efficient use of assets and strong financial health.
Debt Management: Pacira BioSciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.65.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PCRX

Expert Ratings For Pacira BioSciences

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on SLM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLM#NASDAQ">SLM</a>) in the last three months.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $27.2, a high estimate of $29.00, and a low estimate of $25.00. This current average has increased by 7.94% from the previous average price target of $25.20. 
<img src="https://www.benzinga.com/files/images/story/2024/1721919708_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive SLM. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$27.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$29.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Moshe Orenbuch</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$27.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to SLM. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of SLM compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for SLM's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of SLM's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SLM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on SLM analyst ratings.</a>
<h2>About SLM</h2>
SLM Corp is the largest student lender in the country. It makes and holds student loans through the guaranteed Federal Family Education Loan Program as well as through private channels. It also engages in debt-management operations, including accounts receivable and collections services, and runs college savings programs.
<h3>SLM's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining SLM's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 31.49% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 50.84%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): SLM's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 16.34% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): SLM's ROA stands out, surpassing industry averages. With an impressive ROA of 0.99%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: SLM's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.67, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Athenex Inc

News

Latest news for Athenex Inc (OTC:ATNXQ) Stock